The Food and Drug Administration (FDA) is asking for user feedback about CBD to present during the upcoming Convention of Psychotropic Substances, a convention hosted by the World Health Organization (WHO) and overseen by the United Nations. As stated below on regulations.gov:
“The FDA is requesting interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes non-availability for medical use of 17 drug substances. These comments will be considered in preparing a response from the United States to the WHO regarding the abuse liability and diversion of these drugs. WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drugs. This notice requesting comments is required by the Controlled Substances Act (CSA).”
Cannabidiol is just one of 17 substances the FDA hopes to present at the Convention. Although CBD may see the only 1/17th of the floor time, this is nevertheless an incredible leap forward since the CSA classifies cannabis as a Schedule 1 substance, which is defined as “no currently accepted medical use in the United States, high potential for abuse, and lack of accepted safety for use of the drug under medical supervision.”
Clearly, there is a rift between the CSA’s classification of cannabis as being “non-medicinal” within the parameters of being labeled a Schedule 1 substance, versus what the FDA hopes to present with our testimonials.
Perhaps we can ride the UK’s momentum, who recently legalized CBD as a medicinal substance.